Cat. No. | Product name | CAS No. |
DC8186 |
Bexagliflozin(THR1442,EGT1442)|
Featured
Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively. |
1118567-05-7 |
DC3111 |
Canagliflozin
Featured
Canagliflozin is a highly potent and selective SGLT2 inhibitor for CHO-hSGLT2, CHO-rSGLT2 and CHO-mSGLT2 with IC50 of 4.4 nM, 3.7 nM and 2 nM, respectively. |
842133-18-0 |
DC6904 |
DAPAGLIFLOZIN
Featured
DAPAGLIFLOZIN is a SGLT-2 inhibitor. |
461432-26-8 |
DCAPI1573 |
Ipragliflozin (ASP1941)
Featured
Ipragliflozin (ASP1941) is a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects |
761423-87-4 |
DC10765 |
LX-2761
LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control. |
1610954-97-6 |
DC7921 |
Sotagliflozin (LX-4211)
Featured
LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents. |
1018899-04-1 |
DC3108 |
PF-04971729 (Ertugliflozin)
Featured
PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is currently in phase 2 trials for the treatment of diabetes mellitus. |
1210344-57-2 |
DC7826 |
Tofogliflozin hydrate
Tofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2). |
1201913-82-7 |
DC39092 |
Ipragliflozin L-Proline
Featured
Ipragliflozin L-Proline is an orally active and selective inhibitor of SGLT2 with IC50 of 7.38 nM, 6.73 nM and 5.64 nM for human SGLT2, rat SGLT2 and mouse SGLT2, respectively. |
951382-34-6 |
DC44567 |
Ertugliflozin L-pyroglutamic acid
Ertugliflozin (MK-8835, PF-04971729) L-pyroglutamic acid is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2) with IC50 of 0.877 nM for h-SGLT2. Ertugliflozin has the potential for the treatment of typ |
1210344-83-4 |
DC46869 |
Luseogliflozin hydrate
Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM). |
1152425-66-5 |
DC46870 |
Enavogliflozin
Featured
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor. |
1415472-28-4 |
DC48201 |
SGLT1/2-IN-2
SGLT1/2-IN-2 demonstrates potent dual inhibitory activities (IC50 = 96 nM for SGLT1 and IC50 = 1.3 nM for SGLT2). |
2387812-73-7 |
DC72657 |
Velagliflozin proline hydrate
Velagliflozin proline hydrate is the clinical form of Velagliflozin. Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations. |
1661838-94-3 |
DC72658 |
Velagliflozin (proline)
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations. |
1539295-26-5 |
DC72659 |
Sergliflozin etabonate
Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes. |
408504-26-7 |
DC72660 |
Henagliflozin
Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research. |
1623804-44-3 |